LiGalli B.V.
LiGalli is dedicated to revolutionizing women’s healthcare by developing innovative solutions such as the MedRing platform, a personalized intravaginal drug delivery device. The company aims to improve treatment for women through intelligent drug delivery, monitoring, and data collection, addressing the unmet needs in women’s health with a focus on scientific excellence and deep understanding of women’s health.
Industries
Nr. of Employees
small (1-50)
LiGalli B.V.
J.H. Oortweg 21, 2333 CH Leiden, The Netherlands
Patents
Products
The MedRing Platform
A digital platform supporting personalized drug delivery, diagnostics, and bio-signal monitoring through a smart, controlled intravaginal ring.
The MedRing Platform
A digital platform supporting personalized drug delivery, diagnostics, and bio-signal monitoring through a smart, controlled intravaginal ring.
News & Updates
Pharmacokinetic anticholinergic side effect profile comparison of intravaginal and oral oxybutynin: A double-blind, three-way crossover study with the MedRing OAB
A study presented at the International Congress of Pharmaceutical Medicine in April 2025 comparing the pharmacokinetics and side effects of intravaginal versus oral oxybutynin using the MedRing.
Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind study
A clinical trial presented at the British Pharmacological Society’s annual conference in December 2024 demonstrating the efficacy and safety of the MedRing for delivering oxybutynin.
First-in human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring
A 2023 study showing the pharmacokinetics and safety profile of oxybutynin delivered through the MedRing.
Pharmacokinetic anticholinergic side effect profile comparison of intravaginal and oral oxybutynin: A double-blind, three-way crossover study with the MedRing OAB
A study presented at the International Congress of Pharmaceutical Medicine in April 2025 comparing the pharmacokinetics and side effects of intravaginal versus oral oxybutynin using the MedRing.
Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind study
A clinical trial presented at the British Pharmacological Society’s annual conference in December 2024 demonstrating the efficacy and safety of the MedRing for delivering oxybutynin.
First-in human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring
A 2023 study showing the pharmacokinetics and safety profile of oxybutynin delivered through the MedRing.